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Abstract
Background: Early detection of exacerbations by COPD patients initiating prompt interventions
has shown to be clinically relevant. Until now, research failed to identify the effectiveness of a
written individualized Action Plan (AP) to achieve this.
Methods/Design: The current multicenter, single-blind RCT with a follow-up period of 6 months,
evaluates the hypothesis that individualized AP's reduce exacerbation recovery time. Patients are
included from regular respiratory nurse clinics and allocated to either usual care or the AP
intervention. The AP provides individualized treatment prescriptions (pharmaceutical and non-
pharmaceutical) related to a color coded symptom status (reinforcement at 1 and 4 months).
Although usually not possible in self-management trials, we ensured blinding of patients, using a
modified informed consent procedure in which patients give consent to postponed information.
Exacerbations in both study arms are defined using the Anthonisen symptom diary-card algorithm.
The Clinical COPD Questionnaire (CCQ) is assessed every 3-days. CCQ-recovery time of an
exacerbation is the primary study outcome. Additionally, healthcare utilization, anxiety, depression,
treatment delay, and self-efficacy are assessed at baseline and 6 months. We aim at including 245
COPD patients from 7 hospitals and 5 general practices to capture the a-priori sample size of at
least 73 exacerbations per study arm.
Discussion: This RCT identifies if an AP is an effective component of self-management in patients
with COPD and clearly differentiates from existing studies in its design, outcome measures and
generalizability of the results considering that the study is carried out in multiple sites including
general practices.
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Background
Chronic obstructive pulmonary disease (COPD) is charac-
terized by airflow limitation that is not fully reversible.
This airflow limitation is usually progressive and associ-
ated with an abnormal response to noxious particles or
gases [1]. COPD is a major cause of morbidity and mor-
tality throughout the world[2]. Its stable state is inter-
rupted by periods of worsening symptoms which vary in
severity and frequency both during the course of a
patient's illness and between patients. Depending on aeti-
ology and severity, these periods may be referred to as
exacerbations. Exacerbations are important because of
their impact on morbidity and mortality. They may hasten
disease progression by accelerating the decline in lung
function [3,4] and have a significant effect on quality of
life [5,6]. Adjusted for disease severity, patients with exac-
erbations show higher mortality rates than patients with-
out exacerbations [7,8].
According to international guidelines, exacerbations
should be treated with inhaled bronchodilators (particu-
larly inhaled beta2-agonists with or without anticholiner-
gics) and oral corticosteroids. Patients experiencing
COPD exacerbations with clinical signs of airway infec-
tion (e.g., increased sputum purulence) may benefit from
antibiotic treatment [1]. Not all exacerbations are cap-
tured by reliance on healthcare contacts. Previous studies
have shown that less than 50% of exacerbations will not
be reported to the healthcare providers and subsequently
do not receive the correct treatment [9-11]. It is debatable
whether unreported exacerbations are sufficiently mild
that they can be disregarded. More than that, patient rec-
ognition of exacerbations and prompt therapy have
shown to improve exacerbation outcomes [12]. In addi-
tion, patients who refrain from seeking treatment for an
exacerbation or have lower self-management capacity
show higher hospitalization rates compared to those who
seek early treatment from physicians or have better self-
management capacity [13]. This underlines the relevance
of improving self-management skills to enhance early
detection and taking early and appropriate actions by
patients in exacerbation episodes.
Until now, little data is available on which methods are
effective in enhancing self-management associated with
exacerbations. A potential effective method to help
patients to recognize and anticipate on the early symp-
toms of an exacerbation, is an 'action plan' (AP). APs
encourage patients to identify daily variations in symp-
toms and when needed, take the appropriate actions, i.e.
change medication regime, or visit a health care provider.
Until recently, evidence on effectiveness of using APs is
relatively moderate. A systematic Cochrane review includ-
ing only three randomized controlled trials with relatively
small sample size and methodological limitations
showed no effects of APs on clinical COPD outcome
parameters or healthcare resources [14]. Nevertheless, it
was concluded that APs provide an approach to increase
patients' exacerbation-related self-management strategies.
However, data are still insufficient to draw conclusions in
terms of clinical outcomes or healthcare utilization. These
findings highlight the need for continued research in this
field using high quality randomized controlled trials with
adequate sample size.
This present study aims at evaluating the effectiveness of
an AP as an addition to care as usual in a randomized con-
trolled trial. We hypothesize that in the event of an exac-
erbation an AP aiming at early contacting healthcare
providers and thus prompt intervention, leads to faster
recovery in symptoms and health status in patients with
COPD. Secondary outcomes will include self-manage-
ment behaviour such as contact/treatment delay, self-effi-
cacy and healthcare utilization. This article provides a
detailed description of the study background, the targeted
population, study methodology and subsequently com-
pares this with previous randomized trials regarding effec-
tiveness of APs in COPD treatment.
Objectives
Main objective
To evaluate effectiveness of an individualized Action Plan
on health status recovery time (days), in the event of an
exacerbation.
Secondary objectives
To evaluate effectiveness of an individualized Action Plan
on in the event of an exacerbation on, symptom recovery
time (days), treatment delay, healthcare utilisation,
health-related quality of life (HRQL), depression and anx-
iety and self-efficacy.
Methods
Design
The study is conducted as a single-blind randomised con-
trolled trial, with a 6 months follow-up. Patients are ran-
domly assigned to either care as usual or treatment with
an individualized AP as an addition to care as usual. The
randomisation procedure is performed by a respiratory
nurse (RN). To conceal the assignment sequence, a central
web-based service on a 1:1 basis is used. Randomisation is
stratified by centre and gender.
Blinding and ethical considerations
Fundamental bias can be introduced in randomized trials
if patients cannot be masked for the allocated interven-
tion and subjective outcomes are assessed. For obvious
reasons, blinding in behavioural and self-management
interventions is usually not possible. However, a modified
informed consent procedure enables a single-blindBMC Pulmonary Medicine 2009, 9:52 http://www.biomedcentral.com/1471-2466/9/52
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design. In the present study an informed consent to post-
poned information procedure is used, keeping the patient
unaware of the AP being the major study aim. This proce-
dure is used to deal with serious threats to internal validity
and justified since the intervention entails no risk. Using
a regular full informed consent procedure and by absence
of a placebo intervention, patients would be fully aware of
the study purpose and treatment allocation. This aware-
ness of patients might lead to biased results, especially
because the primary outcome measures of this study are
subjective (e.g. HRQoL and symptoms). This postponed
informed consent procedure has shown to be a valuable
solution to obtain valid assessment of subjective out-
comes in a trial in which patients cannot be blinded to the
intervention[15,16], also in patients with COPD [17]. In
addition, in a Dutch cohort, patients did not have objec-
tions to this procedure and did not refuse participation
more often[18]. Our modified informed consent proce-
dure implies that all patients are informed about the fact
that, besides the outcome assessment aiming at gaining
more insight in daily symptom variations, the study has
another purpose. Patients are told that they will be
informed about this additional research question only
after follow-up because informing during recruitment
would affect study results. A letter with postponed infor-
mation about the additional research question, the rand-
omization, allocation and reasons for not informing the
patient during recruitment is sent after the collection of all
outcome data. Meanwhile, the medical ethical committee
of the University Medical Center Utrecht has approved
this procedure (08-275). Using the modified informed
consent procedure in our trial, we deal with the following
threats to internal validity:
Selection bias by attrition or dropout
Patients' preference for allocation to the treatment arm
and receiving "the innovation" above care as usual might
result in increased dropout in the control group, due to
being dissatisfied or lack of interest[19].
Resentful demoralization/compensatory rivalry
Behaviour of the control group may alter as a result of the
study, not due to the independent variable (intervention
vs. control). In our study, the control group might be dis-
satisfied not receiving "the innovation", which increases
the risk of biased results. Changes in outcome may only
be affected due to a demoralized and perhaps less moti-
vated control group not due to the independent variable.
In addition, control patients may compensate by chang-
ing their behaviour, which might result in dilution of the
intervention effect.
Desire to please the investigator/loyalty bias
Patients in the intervention group, who receive "the inno-
vation", might make more favourable follow-up assess-
ments out of loyalty to the programme's staff.
Contamination
By knowing that the AP aims at early recognition and
action in case of changing symptoms, control patients
behaviour might also be influenced by this undesirable
knowledge. If subjects in the control group adopt inter-
vention behaviour, a lack of differences between experi-
mental and control groups may be observed (dilution of
the effect).
This study has been approved by the Medical Ethical
Committee (08-275) of the University Medical Centre
Utrecht. Written informed consent is requested from all
patients prior to participation in the study.
Study population
Patients are selected based on the following inclusion cri-
teria: 1) post-bronchodilator FEV1/FVC ratio < 70%; 2)
age > 40 years; 3) smoking history of more than 20 years
or 15 pack-years; 4) diagnosis of COPD as major function-
ally limiting disease and 5) current use of bronchodilator
therapy. Exclusion criteria are: 1) primary diagnosis of
asthma (onset < 35 years, ≥ 12% post-bronchodilator
reversibility); 2) primary diagnosis of cardiac disease and
3) presence of disease that could either affect mortality or
participation in the study (e.g. confusional states).
Recruitment and informed consent
Patients are recruited from seven regional hospitals and
five general practices in the Netherlands. Inclusion takes
place within a period of 5 months (winter - spring). Med-
ical records of patients with a scheduled visit to a respira-
tory nurse or practice nurse (from here referred to as
respiratory nurse) are screened for in- and exclusion crite-
ria by a respiratory or family physician. Eligible candi-
dates receive an information letter about the content of
the study two weeks prior to a scheduled (regular) visit to
the respiratory nurse (figure 1) including an informed
consent form. One week before this visit, patients are con-
tacted by telephone by one of the researchers to get their
permission to send a baseline assessment questionnaire
and to provide additional information when needed. The
informed consent form and baseline questionnaire are
turned in at the visit to the respiratory nurse.
Control group
Usual care consists of both pharmaceutical and non-phar-
maceutical care according to most recent evidence-based
guidelines on COPD care[1]. At inclusion all patients are
seen by a respiratory nurse who systematically checks and
discusses the following aspects of COPD care: vaccina-
tion, optimizing medication, inhalation techniques, exer-
cise, nutritional aspects, smoking (cessation) and
exacerbation management. When needed, additional
instructions or information is provided including infor-
mation booklets, referral to a physiotherapist, dietician
etc. To control for any co-intervention, all nurses are askedBMC Pulmonary Medicine 2009, 9:52 http://www.biomedcentral.com/1471-2466/9/52
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to record the different aspects discussed in this session.
During follow-up, patients have normal access to their
physician and respiratory nurse. No attempts are made to
change the frequency of scheduled visits.
Intervention
In addition to care as usual, patients in the intervention
group receive an individualized Action Plan. The first ver-
sion of the AP was developed using a combination of the
Anthonisen classification of exacerbation symptoms and
signs[20], and the AP used by Watson et al[21]. To opti-
mize the AP for disease-related patient utilization and to
guarantee that the AP does not conflict with evidence-
based guidelines on COPD care, five experts in the field of
COPD self-management (n = 3) and COPD guidelines (n
= 2) were consulted using semi-structured interviews.
With the resulting version of the AP a pilot study was con-
ducted from December 2007 until May 2008. In this
study, 121 (response rate 71%) COPD-patients (age 67.4
± 10.5 years, FEV1 47.7 ± 18.5% pred) received an AP and
were followed up for 42 days. Thirteen patients were lost
to follow-up (11%). Patients reported both format and
content of this AP as highly satisfactory. In this pilot study
we acquired experience and understanding in patient
recruitment, patient response, study procedures in self-
management research, daily diary symptom assessment/
analysis and patients' perception of AP use.
The final version provides a colour-coded overview of
patients' stable and deteriorated symptom status related
to individualized pharmaceutical and non-pharmaceuti-
cal treatment prescriptions. The backside of the AP
includes three sections which can be used to provide addi-
tional (individualized or general) information on medica-
tion, exercise and nutrition. The AP is printed on A3-sized
paper and folded as a brochure. Standardized instructions
on how to use the AP are provided by the respiratory
nurse. An information brochure is provided as well. In
addition the AP is individualized by the respiratory nurse
together with the patient by filling in 1) a list of important
contact persons and telephone numbers; resource per-
sons: family physician, respiratory physician and respira-
tory nurse; 2) stable symptom severity (individual stable/
normal green zone symptom status); 3) regular medica-
tion/lifestyle prescriptions (green zone); 4) additional
medication/breathing exercises and energy preservation
in case of symptom increase (yellow zone, orange zone);
5) name contact person/telephone number in case of an
exacerbation (orange zone)
The AP is clearly not a one-moment 'paper' intervention.
After being instructed on the individualized AP content
and use, the patient is instructed to bring the AP to every
visit to a healthcare provider. In these follow-up visits, the
AP can be changed or made complete. Within the study
period, there will be two standardized reinforcement ses-
sions by telephone at 1 and 4 months, performed by an
independent respiratory nurse (figure 1). In these ses-
sions, patients understanding and adherence concerning
AP use is evaluated and when needed additional informa-
tion is provided.
Outcomes and measurements
Exacerbations
Exacerbations are detected by daily recording of symp-
toms. Symptoms recorded are termed major and minor
Schematic overview of the study procedure Figure 1
Schematic overview of the study procedure. Patients are recruited and informed, two weeks before randomization. R: 
Reinforcement of AP use by telephone, only for the intervention group.
-2 0 4 81 21 62 02 4
Recruitment
Informed consent
Baseline assessment
Daily symptom registration
3-daily CCQ
 
Follow-up assessment
Postponed information
RR
Randomization
AllocationBMC Pulmonary Medicine 2009, 9:52 http://www.biomedcentral.com/1471-2466/9/52
Page 5 of 10
(page number not for citation purposes)
(figure 2) according to Anthonisen et al[20]. A symptom-
based exacerbation is defined by the onset of two or more
new or deteriorated symptoms, of which at least one
major symptom, persisting for 48 hours or more. A subse-
quent exacerbation is defined as a new event only in the
presence of at least two stable weeks. Exacerbation onset
is defined by the first day on which the symptom criteria
are met. Daily symptoms are binary coded and summed
to give a daily symptom count. Major are scored as: nor-
mal = 0; small increase = 1; or clear increase = 2. The
minor symptoms are scored 0 and 1 respectively. Adding
all these scores results in a daily symptom count with a
range from 0-11 points. Exacerbations are recovered when
the three-day moving mean of the symptom count returns
to the symptom count of days fourteen to eight prior to
exacerbation onset.
Primary outcome
Health status recovery time
The Clinical COPD Questionnaire (CCQ) score is used to
measure disease-related health status. The CCQ is a vali-
dated ten-item questionnaire, divided into three domains:
symptoms, functional state and mental state[22]. In this
study the 24-hour version is used, in which patients are
asked to record their experiences during the last 24 hours.
Recovery time of health status in the event of an exacerba-
tion is defined by the number of CCQ units from the
onset of a symptom-based exacerbation, up to the
moment CCQ score is back to its pre-exacerbation average
(figure 3). If a patient does not fully recover from an exac-
erbation, the CCQ-recovery time is defined by the onset of
the exacerbation and a new stable condition, deflected by
discontinuation of recovery for three consecutive units. A
new stable condition is present when the standard devia-
tion of the new baseline is less than the pre-exacerbation
three units' standard deviation.
Secondary outcomes
Symptom recovery time
Symptom recovery time is calculated as the number of
days from exacerbation onset for the 3-day moving aver-
age of the exacerbation daily symptom count to return to
the mean symptom count on day fourteen to eight preced-
ing exacerbation onset. The use of a 3-day moving average
minimises the effect of day to day variations without bias-
ing the results[12].
Health-related quality of life
The St George Respiratory Questionnaire (SGRQ) is used
to measure health-related quality of life (HRQL). It is val-
idated for measuring health impairment in COPD
patients. The SGRQ consists of sixteen questions in three
domains: symptoms, activity and impact. It assesses
patients' perception of respiratory problems over a pre-
ceding period, ranging from one month to one year, as
well as their current state[23]. Both between group differ-
ences in SGRQ scores will be assessed as well as the pro-
portion of patients crossing the clinical relevant threshold
of 4 points [24].
Unfavourable health status
Unfavourable health status days per patient-year is
defined as the number of days on which the CCQ score is
= the individual CCQ-score mean (total follow-up time)
minus one standard deviation. Each patients' score is
divided by their follow-up time (patient - year).
Symptom-based exacerbation algorithm according to Anthonisen et al Figure 2
Symptom-based exacerbation algorithm according to Anthonisen et al.
Dyspnea
Sputum volume
Sputum purulence
Cough
Sore throat
Common cold
Wheezing
Fever
Dyspnea
Sputum volume
Sputum purulence
≥ 2 consecutive days of: Major
Minor
Dyspnea
Sputum volume
Sputum purulence
Type 1 severe
3/3
Type 2 moderate
2/3
Type 3 mild
1/3
+ ≥ 1/5BMC Pulmonary Medicine 2009, 9:52 http://www.biomedcentral.com/1471-2466/9/52
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Anxiety and depression
The Hospital Anxiety and Depression Scale (HADS) is
used to measure symptoms of anxiety and depression.
Both domains consist of seven statements on emotions or
emotional situations. Patients express their agreement
with the statements on a scale from 0 to 3, which leads to
a maximum score of 21 points for each domain. Scores
between 8 and 11 per domain are suggestive of the pres-
ence of the mood disorder; scores = 11 indicate a probable
presence[25].
Self-efficacy
Exacerbation-related self-efficacy is measured by a self-
developed questionnaire, consisting of 11 items. Patients
are asked to grade their confidence in their own self-man-
agement capabilities in the occurrence of an exacerbation
on a 5-point Likert scale. Lower scores indicate high con-
fidence in adequate exacerbation related self-manage-
ment behaviour. No data is available on validity and
responsiveness of this questionnaire, this will be
addressed simultaneously to the current study.
Contact delay
The number of days between onset of an exacerbation and
contact of a health care provider.
Treatment delay
Number of days between the onset of an exacerbation and
initiation of antibiotics or oral corticosteroids.
Exacerbation rate
￿ Proportion of patients that experience a symptom-based
exacerbation.
￿ Proportion of patients that experience an event-based
exacerbation, i.e. the occurrence of an exacerbation for
which antibiotic or corticosteroid treatment is initiated.
￿ Number of symptom-based exacerbations per patient
year, by dividing each patients' exacerbation rate by their
follow-up time.
￿ Number of event-based exacerbations per patient year,
by dividing each patients' exacerbation rate by their fol-
low-up time.
Health care utilization and cost-effectiveness
The number of respiratory-related hospital admissions,
hospital days, emergency room visits and scheduled and
unscheduled visits or telephone calls to both respiratory
and family physicians are assessed. The proportion of
patients having one or more respiratory-related hospital
admissions is determined, as well as the number of days
between inclusion and first hospital admission.
The perspective of the healthcare payer is adopted for the
cost-effectiveness analysis (CEA). Resource use is valued
in monetary terms by multiplying the units consumed by
the cost per unit[26]. Two major cost categories are distin-
guished: program implementation and direct health care.
Data on cost and outcome are brought together to esti-
mate incremental cost-effectiveness ratios (ICERs) and
subsequently calculated as costs per exacerbation-related
CCQ unit prevented, per hospital admission prevented,
and per health care contact prevented. Sensitivity analysis
is used to test the cost-effectiveness model for methodo-
logical uncertainty and generalizability.
Study procedures
Instruction of healthcare providers
All healthcare providers are well informed about the study
procedures in three, 2-hour meetings with the research
group. They are explicitly instructed not to talk about ran-
domization and allocation to their patients. Written infor-
mation is provided as well.
CCQ recovery time Figure 3
CCQ recovery time. Example of CCQ recovery time in a 
patient with full recovery (A) and a patient who does not 
fully recover but has a new baseline (stable) condition after 9 
days = 3 units (B).BMC Pulmonary Medicine 2009, 9:52 http://www.biomedcentral.com/1471-2466/9/52
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Baseline assessment
Baseline parameters include socio-demographic and
anthropometric parameters, MRC dyspnoea scale, HADS,
SGRQ, the self-efficacy questionnaire and lung function
values. Medical records are checked for the presence of
lung function assessment in the previous three months. If
absent, spirometry is scheduled before inclusion. Post-
bronchodilator Forced Expiratory Volume in one second
(FEV1), Forced Vital Capacity (FVC) and FEV1/FVC ratio
are assessed.
Follow-up assessment
Patients are instructed to record any increase in a predeter-
mined list of symptoms over their chronic (stable) symp-
toms during the previous 24 hours. Every third day the
CCQ is completed. Patients receive six diary booklets,
each consisting of 30 days. After completing one of the
diaries, patients are asked to send them to the investigator.
Every four weeks patients are contacted by telephone to
assess healthcare utilization and to evaluate proper use of
the diary. At 24 weeks, HRQL, anxiety and depression,
dyspnoea and self-efficacy are reassessed. After filling in
the last diary and follow-up questionnaire, patients
receive a postponed-information letter about the aim of
the study and AP and their allocation. Additional data
regarding health care consumption (exact date and con-
tent of visits and interventions) are obtained from medi-
cal records.
Sample size
Based on two studies, a median health status recovery
time around 12 (IQR 8-16) days is expected [9,27]. Unfor-
tunately we do not know the shape of the underlying dis-
tribution. Nevertheless, a nonparametric test might
require either more or fewer subjects compared to a Stu-
dents' t-test, but they never require more than 15% addi-
tional subjects if 1) the number of subjects is reasonably
high: (how high depends on the nature of the distribution
and test, but figure at least a few dozen) and 2) the distri-
bution of the data is not unusual (does not have infinite
tails, in which case its standard deviation would be infi-
nitely large)[28].
Hence, we adopted the general rule for computing the
sample size required for a t-test. In a normal distribution
the distance between the first quartile and the median is
approximately 0.67 times the standard deviation of the
distribution. Thus, if we assume the distribution of recov-
ery time (median = 12, IQR = 8-16) to be normal, the
mean of this distribution will be 12, with standard devia-
tion 6. Sample size is calculated based on the smallest
detectable change of one 3-day CCQ unit. Using the afore-
mentioned 15%-rule, would mean a sample size of 63
(two tailed t-test) * 1.15 (+ 15%) = 73 exacerbations are
needed in both arms to have an 80% chance of detecting
a difference, using a two side alpha = 0.05.
To optimize generalizability, pre-study exacerbation rates
are deliberately not part of the inclusion criteria. The
number of patients needed to obtain 73 exacerbations per
arm depends on the expected 6-months symptom-based
exacerbation incidence. Symptom-based exacerbation
incidence has shown to be at least 50% higher compared
to exacerbations based on healthcare contacts [9-11]. Dif-
ferent prospective cohorts studies using similar symptom-
based algorithms in average populations found (median
or mean) exacerbation rates ranging from 2.53 (IQR 1.33-
3.80)[4], 2.7 (± not-reported), 3.5 (± 2.7)[29] to 5.0 epi-
sodes (IQR, 4.0 to 7.0)[11] per patient per year. Based on
these rates, the proportion of patients experiencing at least
one episode is expected not to be less than 70% and sub-
sequently is a safe boundary. Since symptom-based exac-
erbation recovery is the main outcome measure, dropout
is defined as premature and for any cause interrupting or
ending daily symptom registration, for at least 3 weeks.
Data on dropout rates in similar randomized trials using
daily symptom monitoring are relatively scarce. Two stud-
ies documented a dropout rate of 14% [29] and 12% [30]
respectively.
Presuming a 6-months symptom-based exacerbation inci-
dence of 70%, 15% loss to follow-up and 60% response
rate this means 409 patients need to be recruited to
include 282 patients having 146 exacerbations.
Data analysis
SPSS 15.0 for Windows (SPSS, Inc., Chicago, IL) will be
used for data analysis. Baseline characteristics are
expressed as means and standard deviation or medians
and interquartile range. All data will be analysed as inten-
tion to treat. Differences in CCQ symptom recovery time
between both groups will be evaluated using Mann-Whit-
ney U test. Number of exacerbations will be reported as
weighted exacerbations rates (total number of exacerba-
tions divided by the total person-time of follow up per
group). This approach has shown to produce unbiased
estimates of a weighted statistical approach adjusted for
asymmetry in follow-up times by accounting for each
patient's time spent in the trial [31,32]. Statistical signifi-
cance of weighted rate ratio's are calculated using a Pois-
son regression model including an overdispersion
parameter to account for variability in exacerbation rates
between patients. Other variables will be analyzed using
paired student t-test (continuous data), chi-square test
(binominal data) and Mann-Whitney U  test (ordinal
data). To determine the magnitude of the treatment effect,
Cohen's effect sizes are calculated for continuous varia-
bles measuring differences in pre- and post-change.BMC Pulmonary Medicine 2009, 9:52 http://www.biomedcentral.com/1471-2466/9/52
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Confidence intervals of the incremental cost-effectiveness
ratio's are tested using nonparametric bootstrapping
(Monte - Carlo simulation) drawing 100.000 sam-
ples[33].
Discussion
Early detection of exacerbations by COPD patients has
shown to be clinically important. To achieve this, unfor-
tunately, little data is available on which methods can
enhance exacerbation-related self-management. This also
applies for the potential benefits of AP interventions.
Although comprehensive self-management programs
have been extensively studied, effectiveness of an AP as a
single self-management intervention has been hardly
investigated. A Cochrane review [14] shows that only
three studies evaluated benefits of an AP as a single inter-
vention. These studies teach us that AP's enhance recogni-
tion of exacerbations and taking appropriate action
measures timely, but were clearly underpowered (sample
size) to find effects in the aimed outcome measures. The
current study aims at the evaluation of the hypothesis that
a 'written' AP enhances early detection and prompt action
and is consequently beneficial in exacerbation outcome
(i.e. recovery time).
A priori methodological decisions in the current study are
compared with the strengths and weaknesses from past
randomized trials. The study characteristics (table 1) show
that the current study has some innovative features and
differentiates from the other three studies evaluating iso-
lated effects of an AP as an addition to care as usual.
Within the current study, an intentional multicenter
design, targeting at inclusion from both general practices
as well as outpatient clinics was chosen. This optimizes
not only the external validity of the study allowing better
generalization of the results but also enables to capture
both patients with mild airway obstruction and the most
vulnerable patients (high exacerbation-rates).
Usually, blinding in self-management or educational
interventions is nearly impossible, but the so called 'mod-
ified informed consent' procedure, does enable a single-
blind RCT and consequently compensates for substantial
threats to internal validity. In the field of disease manage-
ment research this can be regarded innovative in terms of
methodology.
In the studies of Wood-Baker et al[34] and McGeoch et
al[35], randomization was clustered to prevent cross-con-
tamination of educational messages within a practice.
Selection bias in cluster randomized trials may threaten
the validity of the results. These studies however did not
inflate their sample size to accommodate for this cluster-
ing effect [36]. We believe that in this robust study (245
patients) the impact of contamination is regulated by the
modified informed consent procedure (patient not know-
ing that the AP is part of the study objective) and the strict
instructions of RN's not to inform control patients about
the existence of the AP. The remaining threat of contami-
nation does not weigh against the disadvantage of the
huge sample size needed in a clustered trial to compensate
for the high inter-cluster variations in both patient (i.e
socioecomic differences) and healthcare (i.e. number and
content of respiratory nurse consultations) characteristics.
Although all studies used an individualized AP, aimed at
early recognition of exacerbations, there are some differ-
ences between the interventions. Instead of encouraging
self-initiation of antibiotics or oral corticosteroids, the AP
used in the current study aims at early contact with a
Table 1: Characteristics of studies evaluating isolated effects of an AP as an addition to care as usual.
Current study Watson Wood-Baker McGeoch
Procedure
Recruitment OC + GP GP GP GP
Pilot-study + + - +
Intervention
- Early contact + + + +
- Self-initiation drugs - + + +
- Reinforcement + - - -
Outcome exa-rt SGRQ SGRQ SGRQ
Validity
Randomization individual individual clustered clustered
Blinding pt + inv - - -
Stratification by centre - - -
Statistics
Follow-up (mths) 6 6 12 12
n5 6 1 0 2 1 5 1
Powered on Δ exa-rt = 1 Δ SGRQ = 5.7 Δ SGRQ = 4 Δ SGRQ = 4
SSC 245 124 124 160
OC, outpatient clinic; GP, general practice; exa-rt, exacerbation recovery time; SGRQ, St George respiratory questionnaire n, number of patients; 
SSC, sample size calculation; pt, patient; inv, investigator.BMC Pulmonary Medicine 2009, 9:52 http://www.biomedcentral.com/1471-2466/9/52
Page 9 of 10
(page number not for citation purposes)
healthcare provider only. The choice to initiate pharma-
ceutical treatment is left to the physician. Moreover, we
have respiratory nurses to evaluate use of the AP and pro-
vide additional information when needed. Reinforcement
has shown to be essential in changing self-management
behaviour, leading to better use of the intervention [37].
Finally, the current study clearly differs from the other
studies in the primary outcome on which the study is
powered. Aiming at evaluating effectiveness of a single
component intervention (AP) necessitates being reserved
on powering on general outcome measures such as hospi-
tal admissions. Therefore, the current study aims at spe-
cific and accurate assessment of effectiveness of the AP on
patient-centred outcomes, in the presence of an exacerba-
tion, since this is what the AP is developed for. In addi-
tion, a clinical relevant advantage of assessing
exacerbation recovery time is that it assesses effectiveness
in all exacerbation episodes and not only those followed
by healthcare contacts or hospital admissions. Effective-
ness in terms of decreased CCQ recovery time is equiva-
lent to a decrease in the impact of these episodes on
health status and thus highly clinical relevant from a
patient perspective. Detecting an effect on recovery time
of exacerbations, the primary outcome, is an essential first
step before trying to prove that the intervention can
increase HRQL or reduce hospital admissions. In conclu-
sion, this RCT identifies whether an AP is an effective
component of self-management in patients with COPD
and clearly differentiates from existing studies in its
design, outcome measures and robustness.
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